Previous Close | 19.48 |
Open | 19.34 |
Bid | 19.07 x 1000 |
Ask | 20.09 x 1000 |
Day's Range | 18.85 - 19.73 |
52 Week Range | 14.62 - 34.72 |
Volume | |
Avg. Volume | 432,901 |
Market Cap | 839.739M |
Beta (5Y Monthly) | 2.68 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.04 |
Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 46.75 |
Subscribe to Yahoo Finance Plus to view Fair Value for INBX
Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that Chiesi Farmaceutici S.p.A ("Chiesi") declined to exercise its option for the ex-North American rights to develop and commercialize INBRX-101 for the treatment of patients with emphysema due to Alpha-1 Antitrypsin Deficiency ("AATD").
In this piece, we will take a look at the 12 best high risk high reward stocks to buy now. If you want to skip our background on investing, then head on over to 5 Best High Risk High Reward Stocks To Buy Now. Investing is a risky endeavor, as is anything that involves the […]
Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has entered into a securities purchase agreement for a private placement financing (the "PIPE") that is expected to result in gross proceeds of approximately $200 million. The financing was limited to certain of the Company's existing investors, which included participation from RA Capital Manage